Indivior Pharmaceuticals (INDV) Cash from Operations (2023 - 2026)
Indivior Pharmaceuticals has reported Cash from Operations over the past 4 years, most recently at 9000000.0 for Q1 2026.
- For Q1 2026, Cash from Operations fell 112.0% year-over-year to 9000000.0; the TTM value through Mar 2026 reached 111000000.0, down 175.0%, while the annual FY2025 figure was 27000000.0, 175.0% down from the prior year.
- Cash from Operations for Q1 2026 was 9000000.0 at Indivior Pharmaceuticals, up from 221000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 158000000.0 in Q2 2025 and troughed at 298000000.0 in Q4 2023.
- A 4-year average of 23076923.08 and a median of 10000000.0 in 2023 define the central range for Cash from Operations.
- Biggest five-year swings in Cash from Operations: skyrocketed 980.0% in 2024 and later crashed 2050.0% in 2025.
- Year by year, Cash from Operations stood at 298000000.0 in 2023, then surged by 94.3% to 17000000.0 in 2024, then plummeted by 1200.0% to 221000000.0 in 2025, then surged by 95.93% to 9000000.0 in 2026.
- Business Quant data shows Cash from Operations for INDV at 9000000.0 in Q1 2026, 221000000.0 in Q4 2025, and 39000000.0 in Q3 2025.